Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).
Type:
Grant
Filed:
March 18, 2022
Date of Patent:
March 26, 2024
Assignees:
MEDIMMUNE LIMITED, ADC THERAPEUTICS SA
Inventors:
Jay Marshall Feingold, David Rodney Ungar
Abstract: The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.
Type:
Grant
Filed:
October 27, 2020
Date of Patent:
February 20, 2024
Assignee:
MEDIMMUNE LIMITED
Inventors:
Catherine Eugenie Chaillan Huntington, Susan Hoe, Prakash Manikwar, Roland Wilhelm Kolbeck, Emma Suzanne Cohen, David Lechuga-Ballesteros, Kellisa Beth Hansen, Dexter Joseph D'Sa, Saba Ghazvini
Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.
Type:
Grant
Filed:
May 28, 2021
Date of Patent:
February 13, 2024
Assignee:
MedImmune Limited
Inventors:
Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
Abstract: The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
Type:
Grant
Filed:
November 17, 2021
Date of Patent:
December 19, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Weidong Hao, Andrew Garcia, Changshou Gao, Isabelle Sermadiras
Abstract: The present invention relates to recombinant polypeptide therapeutics having an engineered O-linked amino acid (AA) glycosylation sequence (motif), which is covalently linked to O-glycan(s) (tag). Recombinant O-glycosylated polypeptides may be produced in mammalian cells to present natural or un-natural O-glycan structures through metabolic labelling.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
December 5, 2023
Assignee:
MedImmune Limited
Inventors:
Adam Tibbles, Monika Papworth, Daniel Higazi, Emmanuel Rossy, Katarzyna Anna Kozakowska, Thomas Vincent Murray
Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
Type:
Grant
Filed:
June 16, 2021
Date of Patent:
October 24, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Isabelle Sermadiras, Monika Anna Papworth, Judy Christiane Paterson, Esther Marie Martin, Peng Ke
Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
Type:
Grant
Filed:
February 16, 2021
Date of Patent:
October 3, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
Type:
Application
Filed:
February 14, 2023
Publication date:
September 28, 2023
Applicant:
MEDIMMUNE LIMITED
Inventors:
Rachel Patricia MOATE, Alex GODWOOD, Ethan Paul GRANT, Martin Michael Kari SCHWICKART, Carlos CHAVEZ, Meina LIANG, Tomas Mikael MUSTELIN, Zhengbin YAO, Koustubh RANADE
Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
Type:
Grant
Filed:
April 10, 2020
Date of Patent:
August 29, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
Type:
Grant
Filed:
November 26, 2019
Date of Patent:
July 4, 2023
Assignees:
MEDIMMUNE LIMITED, GENENTECH, INC.
Inventors:
John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben, Philip Wilson Howard, Luke Masterson
Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
Type:
Grant
Filed:
October 22, 2021
Date of Patent:
May 30, 2023
Assignee:
MedImmune Limited
Inventors:
Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter